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Abstract 
The ESCRT machinery is a group of cytosolic protein complexes whose main function is to form 
intraluminal vesicles. CHMP2B is a protein subunit of the ESCRT III complex which, when 
mutated, has been seen to cause a rare familial form of frontotemporal dementia. These 
mutations produce aberrant endocytic and autophagic activity within cells. Astrocytes have 
been implicated in virtually all neuropathologies and are responsible for a variety of key 
functions in the brain, one of which is glutamate regulation. CHMP2B has been reported to be 
ubiquitously expressed however no research has specifically investigated it in astrocytes 
despite their emerging role in these neuropathologies including frontotemporal dementia. This 
project aimed to determine CHMP2B expression in astrocytes and elucidate whether the FTD 
associated mutation CHMP2BIntron5 affected basic astrocyte biology. Western blotting and 
immunofluorescence staining of cell lines was conducted to confirm expression of CHMP2B in 
astrocytes and revealed that CHMP2B is expressed in astrocytes. Following confirmation of 
expression transient transfection of cells was used to create an expression model of 
CHMP2BIntron5 in order to analyse the effects of this mutation on cell morphology and 
localisation of the glutamate transporters EAAT1 and EAAT2. Morphological analysis showed 
no difference in cells when comparing CHMP2BWT and CHMP2BIntron5 nor was any difference in 
glutamate transporter localisation observed. This project did not find any alterations to basic 
astrocyte biology when exposed to mutations in CHMP2B.  
1. Introduction 
Endocytosis is an integral process within all cells to ensure proper internalisation, recycling and 
degradation of proteins (Piper and Katzmann, 2007). Degradation of proteins is pivotal for 
removal of misfolded or defective proteins to make sure aberrant signalling or aggregation 
does not occur. Internalisation of surface receptors is also important for regulation of cellular 
signalling (Babst et al., 2002). In neurons, endocytosis is vitally important in recycling of 
synaptic vesicles and neurotransmitter receptor availability at synapses. These are 
fundamental to ensure neurotransmission is occurring correctly as defects in this can lead to 
aberrant activity within the brain (Saheki and De Camilli, 2012). Endocytosis in neurons is also 
important for internalisation of neuronal growth factors which initiate signalling cascades that 
are key for a variety of functions such as axonal growth, cell survival and dendritic branching 
(Cosker and Segal, 2014). Furthermore due to the length of neurons signals must sometimes 
travel a long way so transport via endosomes helps in signalling across long distances. 
2 
 
One specialised subtype of endosome are known as multivesicular bodies (MVBs). What makes 
these endosomes special is that they contain intraluminal vesicles which are formed by inward 
budding of the endosomal membrane away from the cytoplasm (Alonso Y Adell and Teis, 
2011). This mechanism is often used for endocytosis of receptors which must be degraded in 
order to inhibit cellular signalling. By forming an intraluminal vesicle the signal from the 
receptor cannot be transmitted as it is contained within the vesicle.  The formation of 
intraluminal vesicles is a complex task which is carried out by the endosomal sorting complex 
required for transport (ESCRT) machinery (Stuchell-Brereton et al., 2007). 
1.1 ESCRTs 
The ESCRT machinery comprises a group of cytosolic protein complexes which have the unique 
ability to bend the membrane away from the cytoplasm in order to create intraluminal vesicles 
as part of the MVB pathway and also are utilised for cytokinesis (Schmidt and Teis, 2012; 
Woodman, 2016). There are four sub-complexes which make up the ESCRT machinery; ESCRT 
0, ESCRT I, ESCRT II, ESCRT III along with the ATPase Vaculolar protein sorting-associated 
protein 4 (VPS4) (Alonso Y Adell and Teis, 2011). Each of these complexes has a unique and 
sequential role in the formation of intraluminal vesicles for the sorting of proteins within the 
endosome (Henne et al., 2011).  
ESCRT 0 is responsible for initiation of the MVB pathway and also for sorting of ubiqutinated 
proteins in the endosome. ESCRT I and II are thought to work together to help stabilise the 
vesicles that are formed (Schmidt and Teis, 2012). ESCRT III is thought to also be involved in 
the sorting and recycling of cargo as it is able to recruit deubiqutinases to the forming vesicles 
and also to provide a binding site for the final component, VPS4, to bind (Babst et al., 2002). 
VPS4 is a AAA type ATPase (ATPases associated with diverse cellular activities) which is 
required for the scission of the vesicles and for disassembly of the complex (Davies et al., 
2009). Each of the subunits of ESCRT-III contains a microtubule interacting and trafficking 
interacting motif (MIM) which are important for binding and forming the ESCRT-III complex 
and is key for interaction with VPS4 (Stuchell-Brereton et al., 2007). 
ESCRT-III comprises of four core subunits; CHMP2 (A and B), CHMP3, CHMP4 (A – C) and 
CHMP6. Along with these there are three accessory components; CHMP1 (A and B), CHMP5 
and Ist1 (Schmidt and Teis, 2012). Unlike the other ESCRT complexes, ESCRT-III does not form a 
stable complex in the cytoplasm so only forms transiently on endosomes when needed (Babst 
et al., 2002). Mutations altering any subunit or accessory component can significantly affect 
formation of ESCRT-III and subsequently hinder its function. 
3 
 
Mutations affecting ESCRT III have been linked to a variety of disorders including Fragile X 
syndrome, hereditary spastic paraplegia, amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD) (Hurley, 2010; Krasniak and Ahmad, 2016; Vita and Broadie, 
2017). Mutations in the ESCRT-III subunit charged multivesicular body protein 2B (CHMP2B) 
has been implicated in a rare familial form of FTD (van der Zee et al., 2008). 
1.2 CHMP2B 
CHMP2B is a component of the ESCRT-III complex whose role is to provide the binding site 
required by the ATPase VPS4 in order to catalyse the membrane scission of intraluminal 
vesicles and induce dissociation of the ESCRT-III complex. Previous reports have shown 
CHMP2B to be expressed in all neuronal populations and is most highly expressed in the 
olfactory bulb and cerebral cortex (Ferrari et al., 2010). Aside from its role in the ESCRT-III 
complex, CHMP2B has been implicated in synapse formation and synaptic plasticity 
(Chassefeyre et al., 2015). Upon depletion of CHMP2B it has been observed that in cultured 
neurons there is reduction in dendritic branching and synaptic potentiation (Belly et al., 2010). 
One report showed a correlation between CHMP2B transcription levels and amount of 
synaptogenesis, however there is little research and not much is known about how they may 
be linked (Chassefeyre et al., 2015).  
Structurally CHMP2B comprises a coiled coil domain at the N terminus and a MIM at its C 
terminus (van der Zee et al., 2008). Mutations of CHMP2B linked to neurodegenerative 
diseases (including FTD) often occur in this MIM region and result in truncations at the C 
terminus. Normally VPS4 binds to CHMP2B at its MIM; however mutations which affect this 
region inhibit VPS4 from binding which may inhibit membrane scission and dissociation of 
ESCRT III (Stuchell-Brereton et al., 2007).  Furthermore when not required as part of ESCRT III, 
CHMP2B exists in an auto inhibited state wherein the N and C terminus are bound together 
(Krasniak and Ahmad, 2016). Mutations to the C terminus result in this binding site no longer 
being present thus CHMP2B cannot be inhibited. It has been reported that in some cases 
membrane protrusions occur on the cell surface where there are mutations in CHMP2B  which 
may be linked to its inability to auto-inhibit itself (Krasniak and Ahmad, 2016). Furthermore 
mutations in CHMP2B have been seen to cause abnormal autophagic and endocytic activity 
(Krasniak and Ahmad, 2016).  
The most common FTD-associated CHMP2B mutation occurs at a splice site of intron 5 where a 
G to C base change results in the intron remaining rather than being spliced out resulting in 
two splice variants, CHMP2BIntron5 and CHMP2BΔ10. CHMP2BIntron5 lacks the final 36 amino acids 
which are instead replaced with a single Valine residue (Isaacs et al., 2011; Clayton et al., 
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2015).  In CHMP2B Δ10 the final 36 amino acids are replaced with 29 nonsense residues. Both of 
these variants have been reported in a single Danish family with this mutation which causes a 
rare form of FTD known as FTD-3 (van der Zee et al., 2008).  
1.3 CHMP2B in Neurodegenerative disease 
Mutations in CHMP2B have been implicated in a rare form of FTD, known as FTD-3. FTD-3 is a 
rare autosomal dominant form of FTD which arises due to mutations on chromosome 3. FTD,  
the second most common form of dementia after Alzheimer’s disease, comprises a group of 
neurodegenerative disorders which have overlapping symptoms including atrophy of the brain 
in the frontal and temporal lobes, behavioural changes, language problems and reduced motor 
functions (Goedert et al., 2012). There is considered to be an overlap between FTD and ALS 
due to the common overlap of symptoms observed in each disease. ALS is a disease in which 
there is progressive degeneration of both upper and lower motor neurons (Ince et al., 2011). A 
recent study by Vernay et al. (2016) using a transgenic mouse model expressing CHMP2BIntron5 
found that there both the behavioural and histological features observed were reminiscent of 
both FTD and ALS. Other research has also highlighted the possibility of ALS and FTD existing 
on a spectrum (Ferrari et al., 2011; Radford et al., 2015). Furthermore mutations in CHMP2B 
have been linked to cases of both sporadic and familial ALS, however this has only been 
observed in approximately 1% of cases (Chen et al., 2013). 
In studies using immunohistochemistry on post-mortem human brain tissue, CHMP2B has 
been found to co-localise with granuovacuolar degeneration (GVD) bodies (Yamazaki et al., 
2010). These GVD bodies are large double membrane-bound vacuoles containing a central 
granule (Funk et al., 2011). GVD bodies are a common feature in Alzheimer’s disease with beta 
amyloid accumulation seen within them (Willén et al., 2017). Furthermore a correlation was 
found between episodic memory decline and GVD body formation in AD which implicates a 
role of perturbed autophagy and endocytosis in AD (Yamazaki et al., 2010). 
Changes to neurons have been noted in cases of CHMP2B mutation which include; axonal 
swelling, decrease in dendritic arborizations and a decrease in the number of mushroom 
spines (Chassefeyre et al., 2015). Alongside this it has also been found that there were 
decreases in long term potentiation. This indicates a further role of CHMP2B in synaptic 
maintenance and generation.  
It has also been seen that aggregates are present within microglia as well as neurons in cases 
of FTD caused by mutated CHMP2B (Isaacs et al., 2011). This is probably due to the microglia 
attempting to clear the GVBs, however it has been shown that the aggregates within microglia 
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are often larger than that in neurons which could imply that the microglia also express the 
mutant CHMP2B.  
Impairments in endocytosis have been linked to a variety of other neurodegenerative diseases 
including AD, Huntington’s disease and Parkinson’s disease (Frake et al., 2015). It has been 
reported that neurons are more susceptible to faults in endocytosis in comparison to other 
cells, however the reason for this is not understood (Cosker and Segal, 2014). 
Research investigating the role of CHMP2B in neurons has begun to identify its importance 
however no research has ever investigated the role of CHMP2B in astrocytes, a key neural cell 
type responsible for homeostasis in the brain. It has been stated that CHMP2B is ubiquitously 
expressed in the brain so it would be reasonable to assume it would also be expressed in 
astrocyte populations, yet this has not been experimentally confirmed. Research investigating 
astrocytes and their role in neurodegenerative disease is still extremely limited. 
1.4 Astrocytes  
A neurocentric view of neurodegenerative diseases has been held for many years in which it 
was thought that neurons alone were solely important in neurodegeneration. However 
research is demonstrating that glial cells are also affected in neurodegenerative diseases. 
Astrocytes have been seen to have an effect on neurodegeneration and in turn can also be 
affected by neurodegeneration (Maragakis and Rothstein, 2006; Lobsiger and Cleveland, 
2007).  It has not been well studied what role astrocytes play in neurodegenerative diseases 
but astrocytic dysfunction has been implicated and reported in cases of AD, ALS and 
Parkinson’s disease (Maragakis and Rothstein, 2006). 
Astrocytes are vital for normal functioning within the brain; they play roles in areas such as 
regulating cerebral blood flow, maintenance and formation of synapses and neurotransmitter 
regulation (Lobsiger and Cleveland, 2007). They also play a vital role in glutamate regulation at 
synapses through the expression of glutamate transporters (Malarkey and Parpura, 2008). 
Glutamate is the principal excitatory neurotransmitter in the brain; it is a key transmitter in 
both neurons and glial cells (Lobsiger and Cleveland, 2007). Astrocytes in particular are able to 
control glutamate levels through a variety of release and uptake mechanisms (Malarkey and 
Parpura, 2008). Glutamate acts as a gliotransmitter and is important for astrocytic modulation 
of synaptic plasticity (De Pittà and Brunel, 2016).  The excitatory amino acid transporter (EAAT)  
family of glutamate transporters are important in glutamate regulation in astrocytes 
(Schousboe and Waagepetersen, 2005).There are five known EAAT transporters known as 
EAAT 1 – 5(Fahlke et al., 2016).  EAAT 1 and 2 are both expressed in astrocytes and EAAT2 is 
responsible for the uptake of approximately 90% of glutamate into astrocytes (Ugbode et al., 
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2017).  EAAT3 and EAAT4 are both expressed primarily in neurons while EAAT 5 is expressed in 
the retina (Lin et al., 2012). 
Changes in glutamate transporters have been implicated in various neurodegenerative 
diseases. For example mutations to glutamate transporters have been implicated in 
Alzheimer’s disease (Jacob et al., 2007; Cassano et al., 2012; Han et al., 2016). These mutations 
have been seen to produce accumulation of glutamate at the synapse which leads to 
excitotoxicity and subsequently cell death (Lin et al., 2012; Han et al., 2016). In Alzheimer’s 
disease it has been reported that there is a decrease in glutamate transporter function and 
reduced EAAT2 expression in the brain, however it is unknown what causes this (Lin et al., 
2012).  
It has also been reported that there is a loss of synapses in the frontal and temporal lobes in 
cases of FTD (Clare et al., 2010). Since it is known that astrocytes play an important role in 
synapse regulation and that one of their main functions is glutamate handling it could be 
proposed that impairment to glutamate handling may play a role in this synapse loss observed. 
There has been very little research conducted looking at the role of the glutamate transporters 
in FTD so it is unknown what role they may play here. Hence more research is needed 
investigating these transporters in FTD. 
Astrocytes are stellate shaped cells but are highly heterogeneous in their morphology and 
function which is a reflection of their subtype and localisation within the brain (Oberheim, 
Goldman and Nedergaard, 2012; Pekny and Pekna, 2016). The shape of astrocytes is vital for 
their particular functions in the many different roles they undertake. Astrocytes are able to 
change their shape and size following central nervous system damage in a process known as 
reactive gliosis (Olabarria et al., 2010; Pekny and Pekna, 2016). Reactive gliosis aims to protect 
the cells of the brain from further damage through isolation of the damaged areas, 
reconstruction of the blood-brain barrier and remodelling of neuronal circuits (Olabarria et al., 
2010; Burda and Sofroniew, 2014). 
1.5 Astrocytes in Neurodegenerative diseases 
There have been a multitude of theories developed as to how astrocytes are affected in 
neurodegenerative diseases and what role they play there. These include alterations in calcium 
signalling, impaired glutamate transport and altered glial fibrillary acidic protein expression 
(Maragakis and Rothstein, 2006).  
Previously it was thought that cell populations were independently vulnerable to toxicity and 
could not affect one another. However recent research has been challenging this idea and in 
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many neurodegenerative diseases non-cell autonomous effects have been implicated (Lobsiger 
and Cleveland, 2007; Ilieva et al., 2009). For example, a study by Meyer et al. (2014) 
investigating sporadic and familial ALS found that non-cell autonomous activities by astrocytes 
had an effect on toxicity in motor neurons in both familial and sporadic forms of the disease. 
Another study wherein co-culturing of healthy neurons with glial cells expressing a mutant 
form of presenilin 1 found that there was inhibition of neurogenesis (Choi et al., 2008). 
In the case of ALS wherein there is death to motor neurons, research has shown that the 
motor neurons alone expressing a disease causing mutation is not enough to cause ALS 
(Phatnani and Maniatis, 2015). Research by Di Giorgio et al. (2007) found that astrocytes 
expressing ALS mutations directly contributed to the death of motor neurons in vitro. 
Furthermore research by Nagai et al. (2007) also found that these astrocytes are selectively 
toxic to motor neurons which provides evidence that astrocytes do play a role in ALS. 
Furthermore it has been seen in cases of FTD, Huntington’s disease and AD that neurons which 
are surrounded by astrocytes harbouring mutations often develop aggregates and are more 
prone to cell death (Radford et al., 2015).  
Reactive gliosis has also been implicated in various neurodegenerative diseases including ALS 
and AD (Olabarria et al., 2010; Verkhratsky et al., 2014; Jones et al., 2017). In the case of AD it 
has been shown that amyloid beta plaques and fragments are able to stimulate reactive gliosis 
(Phatnani and Maniatis, 2015).  Reactive gliosis have been reported to occur in areas of 
neuronal loss in both ALS and FTD (Brettschneider et al., 2012; Radford et al., 2015). Reactive 
gliosis has also been implicated in FTD (Ilieva et al., 2009). 
Collectively, these studies indicate that astrocytes play a role in neurodegenerative diseases 
and therefore need to be investigated further to understand their roles and functions to offer 
new perspectives on such diseases and provide new targets for therapy. To date, there has 
been no research investigating the function of CHMP2B in astrocytes. Indeed, it remains 
unconfirmed whether CHMP2B is expressed in astrocytes, and if so what affect FTD-associated 
mutations may have on astrocytes. 
This project aims to identify the effects of FTD-associated mutant forms of the protein 
CHMP2B on astrocytes. This will be achieved through: 
1. Confirmation of CHMP2B expression in astrocytes by western blot and 
immunofluorescence 
2. Creation of an expression model for experimentation by transient transfection of wild-
type and mutant CHMP2B into HeLa and 1321N1 cell lines alongside a GFP reporter 
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3. Assessment of morphological changes to cells expressing mutant CHMP2B as an 
indicator of cellular stress 
4. Investigation of changes to glutamate transporter localisation in cells expressing the 
CHMP2B mutation as an indicator of astrocyte function 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Reagents  
Unless otherwise stated all reagents used were purchased from Fisher (Loughborough, UK) and 
were of reagent grade or higher. 
2.1.2 DNA Plasmids 
All the DNA plasmids used in this project are listed in table 1. pEGFP-C1 was from Clontech. All 
other plasmids were a gift from Y. Goldberg (Grenoble institute of Neuroscience, Grenoble, 
France). 
Plasmid Gene Protein Short name 
pEGFPC1 EGFP Green fluorescent protein pEGFP-C1 
pcDNA3.1_CHMP2BWT CHMP2B Charged multivesicular body protein 2B CHMP2BWT 
pcDNA3.1_CHMP2BI5 CHMP2B Charged multivesicular body protein 2B 
with intron 5 mutant 
CHMP2BI5 
pBI-empty  Empty Vector pBI-empty 
Table 1. List of DNA plasmids used in this project  
2.1.3 Antibodies 
All primary and secondary antibodies that were used for western blotting (WB) and 
immunofluorescence (IF) are listed in Table 2. 
Antibody Species Origin Dilution 
Anti-CHMP2B Rabbit Abcam, Cambridge, UK 1:200 (IF) 1:5000 (WB) 
Anti-EAAT1 Rabbit Abcam. Cambridge, UK 1:200 (IF) 
Anti-EAAT2 Rabbit Abcam, Cambridge, UK 1:200 (IF) 
Anti-beta actin Mouse Abcam, Cambridge, UK 1:10,000 (WB) 
Goat Anti-Rabbit HRP Goat Abcam, Cambridge, UK 1:5000 (WB) 
Rabbit Anti-Mouse Rabbit Abcam, Cambridge, UK 1:5000 (WB) 
Alexa Fluor 555- Goat Invitrogen, Paisley, UK 1:200 (IF) 
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conjugated Anti-Rabbit 
Alexa Fluor 555-
conjugated Anti-Mouse 
Goat Invitrogen, Paisley, UK 1:200 (IF) 
Table 2. List of primary and secondary antibodies used in this project 
2.2 Bacterial transformation and DNA Preparation 
All bacterial work was carried out using aseptic technique. In order to amplify plasmid DNAs 
for subsequent transfections 1µg of DNA was added to 50µl of competent Stbl3 E.coli 
(Invitrogen) and incubated on ice for 30 minutes. Following incubation, the bacteria were heat 
shocked at 42°C for 45 seconds and returned to ice for a further two minutes. 250µl of SOC 
medium (2% Tryptone, 0.5% Yeast Extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2.6H2O, 20mM 
Glucose) was added and placed into a shaking incubator at 37°C for 1 hour to allow for 
recovery. 100µl of bacteria were then plated onto agar plates containing either ampicillin or 
kanamycin at a concentration of 50μg/ml and incubated at 37°C overnight. Single colonies 
were selected and grown overnight in 50ml of Luria-Bertani broth (Fisher). Plasmid extraction 
and purification was conducted using the Qiagen Hi-Speed plasmid maxi kit as per the 
manufactures instructions. Concentrations of DNA were determined using a NanoDrop 2000 
spectrophotometer. The absorbance was measured at 260nm. 
2.3 Cell Culture 
The human brain astrocytoma cell line 1321N1 and the human cervical cancer cell line HeLa 
were cultured in Dulbecco’s modified essential medium (DMEM) and Eagle’s minimum 
essential medium (EMEM) respectively, each supplemented with 10% fetal bovine serum, 
2mM L-glutamine, 1mM sodium pyruvate, 100U/ml penicillin and 100U/ml streptomycin. Both 
cell types were maintained at 37°C and 5% CO2. Cell lines were passaged every 3-4 days when 
80% confluency was reached. HeLa cells were used as a non-glial control as CHMP2B is known 
to be naturally expressed in this cell type (Atilla-Gokcumen et al., 2014).  
2.4 Transfections 
Transfections using plasmid DNA were conducted using the LipofectamineTM 3000 kit 
(Thermofisher). Cell lines were seeded onto coverslips in 12 well plates at a density of 70,000 
cells and were left 24 hours to achieve approximately 60% confluency at time of transfection. 
Optimisation of transfections was undertaken using the pEGFPC1 plasmid as per the 
manufacturer’s guidelines. 4 hours prior to transfection the media was changed. The cells were 
left in the transfection mix for 18 hours and then the media was replaced.   
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2.5 Fixing and Staining  
Cells were fixed in 4% formaldehyde in PBS for ten minutes. This was followed by 0.1M glycine 
in PBS to quench any unreacted aldehydes for a further ten minutes. Membrane 
permeabilisation was carried out with 0.1% Triton X100 for four minutes. The primary 
antibodies were diluted in PBS and applied to the coverslips. These were incubated for 30 
minutes and then washed three times in PBS. This was followed by incubation in the secondary 
antibody in the dark for 30 minutes. During incubation with the secondary antibody DAPI was 
also added at a concentration of 1μg/ml. The coverslips were washed again three times in PBS 
and then mounted onto microscope slides using ProLong Diamond anti-fade mountant 
(Invitrogen). Slides were left to cure for 24 hours and then were sealed using nail varnish. 
2.6 Fluorescence microscopy and image analysis  
The fixed cells were visualised using a Zeiss Cell Observer z-sectioning fluorescence imaging 
system equipped Zeiss definite focus, HXP 120 V illumination and FITC, GFP,  DsRed and DAPI 
filter sets. Fluorescence images were acquired using × 20 PL Apo (0.8 NA), × 40 EC Plan-
Neofluar (1.3 NA) oil and × 63 PL Apo (1.4 NA) oil objectives, AxioCam MRm Rev.3 CCD camera 
and ZEN Pro software (Carl Zeiss, Cambridge, UK).  
Three coverslips and a minimum of five random fields of view were analysed for each 
experiment. Images were analysed using FIJI ImageJ software.  
2.7 SDS PAGE and Western Blotting  
Cells were lysed in RIPA lysis buffer (50mM Tris, 150mM NaCl, 0.5% sodium deoxycholate, 1% 
Triton X-100, 0.1% SDS and a HaltTM Protease Inhibitor Single-Use Cocktail). A Pierce BCA assay 
kit (Thermo Scientific) was used to determine protein concentration in each lysate sample as 
per the manufacturer’s guidelines. 10μg of each sample was mixed with equal volumes of 2x 
Laemmli buffer and boiled for five minutes. Samples were loaded onto a Bio-Rad Mini-
PROTEAN 10% Tris-Glycine gel and run at 100V for 90 minutes in 1x Tris/Glycine/SDS running 
buffer (Bio-Rad, Watford, UK). The resolved proteins were transferred onto nitrocellulose at 
300mA for 90 minutes in 1x Tris/Glycine transfer buffer (Bio-Rad). The blot was blocked 
overnight in 5% milk in tris-buffered saline and tween 20 (TBST) at 4°C. The blot was then 
probed in the anti-CHMP2B primary antibody for 4 hours. Following incubation in the primary 
antibody the blot was washed three times for five minutes each before the secondary antibody 
was applied and incubated for 1 hour. The blot was then washed again before ECL reagent was 
applied and visualisation was conducted using Bio-Rad Gel Doc XR+ system. The blot was then 
stripped and re-probed using anti-beta actin for use as a loading control. 
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2.8 Statistical analysis 
All statistical analysis was conducted using IBM SPSS Statistics 24. Unless otherwise stated all 
data was normally distributed (as determined via Q-Q plots and Shapiro Wilks test) and had 
equal variances (Homogeneity of Variance test). Multiple comparisons were carried out using a 
One-way ANOVA followed by Tukey’s post-hoc. A p-value of 0.05 or lower was considered 
significant throughout. 
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3. Results 
3.1 Confirmation of CHMP2B in astrocytes 
In order to confirm basal expression of CHMP2B in astrocytes; whole cell lysates of the glioma 
cell line 1321N1 (a commonly used astrocyte cell line) and primary normal human astrocytes 
were analysed by SDS-PAGE and western blot using an established and commercially available 
CHMP2B antibody. HeLa cells were used as both a non-glial control and as a positive control, as 
CHMP2B expression in this cell line has already been confirmed elsewhere. At a standard load 
of 10μg per lane, a single band was observed at approximately 25kDa for all cell types, 
corresponding to the size of CHMP2B which has a predicted molecular weight of 24kDa (Figure 
3.1.1 A). All bands appeared to be of a similar thickness with the HeLa cells being slightly 
fainter. An anti-beta actin antibody was used as a loading control. The levels of actin appeared 
to be similar in the NHA’s and 1321N1 cell line, but the band in the HeLa cells was much fainter 
indicating an unequal load. In order to overcome these apparent loading issues and to provide 
a semi-quantitative measure of relative CHMP2B levels in each cell type, densitometry was 
performed on the western blot using ImageJ (Figure 3.3.1 B). The relative densities were 
generated by normalisation of the CHMP2B bands against the beta actin band. Normal human 
astrocytes were seen to have the highest relative density at 2.05 which was followed by 
1321N1 cells with a relative density of 0.79. HeLa cells had the lowest relative density at 0.43. 
It was only possible to undertake densitometry on a single blot due to issues with blot quality, 
hence statistical analyses could not be carried out.  
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Further confirmation of basal CHMP2B expression in astrocytes was completed using 
immunocytochemistry and fluorescence microscopy. Validation of primary antibodies was 
undertaken, initially in HeLa cells. Unstained cells were used as negative controls and showed 
no signal in the dsRED channel (Figure 3.1.2 A-C). When the primary anti-CHMP2B antibody 
was used alone no fluorescence was observed (Figure 3.1.2 D-F). This was the same when the 
Alexa-Fluor 555-conjugated secondary antibody alone was used (Figure 3.1.2 G-I). When the 
anti-CHMP2B antibody was followed with the secondary antibody fluorescence was seen in all 
cells, as expected.  
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Antibody validation of the anti-CHMP2B antibody was then completed in 1321N1 cells to 
ensure the staining was similar to HeLa cells. For this unstained cells were used as controls 
from which to compare all other conditions to, wherein no fluorescence was seen in the dsRED 
channel (Figure 3.1.3 A-C). Both the cells which had been treated with the primary antibody 
only or the secondary antibody only were visually identical to the unstained cells in the dsRED 
channel as no fluorescence was seen (Figure 3.1.3 D-I). When both the primary and secondary 
antibodies were used in conjunction staining was observed in 1321N1 cells in the same 
manner as the HeLa cells. This further confirms the expression of CHMP2B in astrocytes. 
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Mean fluroescence intesities of the cells stained for CHMP2B were measured using imageJ and 
compared to determine if any differences in expression levels were seen btween the two cell 
types. No significant difference was found between the fluroescence intensities of the two cell 
types. The mean pixel density for HeLa cells was 4,105,558 ± 815,404 whilst the 1321N1 cells 
had a mean pixel density of 3,882,177 ± 1,378,401(n=10). 
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In order to gain insight into the sub-cellular localisation pattern of CHMP2B in astrocytes, high 
magnification fluorescence images were taken 1321N1 cells and HeLa cells.  The high 
magnification images showed CHMP2B expression throughout the cell in a punctate manner 
but absent from the nucleus in both cell types (Figure 3.1.5).  
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3.2 Creation of GFP expression model  
Following confirmation of CHMP2B expression in astrocytes it was necessary to express 
mutant forms of the protein. An expression model was created using Lipofectamine 3000™ 
(referred to herein as simply Lipofectamine) reagent to allow transient transfection of DNA 
encoding wild-type or mutant CHMP2B to the 1321N1 astrocyte cell line and HeLa cells, as a 
non-astrocyte control. 
To optimise the transfection protocol, different ratios of Lipofectamine reagent and DNA were 
trialled. pEGFP-C1 was utilised in these experiments to permit simple quantification of 
transfected cells by virtue of them being positive for expression of GFP. Varying ratios of 
Lipofectamine to DNA were trialled; 1.5μl, 2μl and 3μl of Lipofectamine reagent were used 
with 1μg or 2μg of DNA (Figure 3.2.1). 
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In the case of the HeLa cells, 2µg of DNA gave a consistently higher percentage of GFP positive 
cells across all Lipofectamine volumes (ANOVA F(5,12)=19.036, p<0.001; Figure 3.2.3A). Although 
a trend towards higher volumes of Lipofectamine yielding a greater percentage of transfected 
cells was seen, overall there was no significant difference in the percentage of transfected cells 
across the reagent volumes tested. For 1321N1 cells, there was no significant difference in 
transfection efficiency between 1µg and 2µg DNA across any volume of Lipofectamine; 
however, with 2µg DNA a volume of 3µl Lipofectamine (but not 2µl) did prove significantly 
more effective than 1.5µl (ANOVA F(5,12)=7.851, p=0.002; Figure 3.2.3B). Hence, it was 
determined that a ratio of 3μl of Lipofectamine reagent with 2μg of DNA would be most 
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effective across both cell types. For the HeLa cells an average 72.3±7.5% of cells were 
transfected at this ratio while in the 1321N1 cells it resulted in an average efficiency of 
22.3±1.5%. The ratio of 2μg DNA and 3μl Lipofectamine was therefore used for all subsequent 
transfections. 
 
Once it was determined which ratio of DNA to Lipofectamine to use further, experiments were 
conducted to identify any effects from Lipofectamine treatment on cell growth. Both HeLa and 
1321N1 cells were subjected to treatment with Lipofectamine only (to test the direct effect of 
this reagent on cell growth), Lipofectamine plus an empty vector (pBI-empty; to assess the 
effect of lipid-DNA particles on cell growth) and lipofectamine plus an expressing vector 
(pEGFP-C1; to address the effects of CMV-mediated overexpression of a protein on growth). 
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For each cell type, a control of untransfected cells was used; these cells underwent a normal 
medium change at the time the treatment groups were exposed to lipofectamine. Cell 
confluency was estimated at 24 and 48 hours post-treatment to determine if any condition 
impacted cell growth or survival. Cell growth changes were compared using a one-way ANOVA 
and Tukey’s post-hoc. For both cell types, in all but one case, there was a significant increase in 
cell confluency between 24 and 48-hours post-treatment, indicating that cells continued to 
grow irrespective of treatment (HeLa, F(7,72)=9.960, p<0.001; 1321N1, F(7,72)=11.656, p<0.001; 
Figure 3.2.2). In the case of the Lipofectamine only-treated HeLa cells, there was an increase 
seen between 24 and 48 hours in all repeats, however this was shown to be not significant 
(p=0.099). Comparisons between treatments revealed no significant difference in confluency 
levels for either cell type under any treatment condition when compared to the non-
transfected control. Hence, the project proceeded on the basis that Lipofectamine had no 
negative impact on cell growth. 
In order to ensure the transfection protocol was capable of delivering the DNA plasmids and 
also non-toxic to the cells, pEGFP-C1 was used to allow visualisation of cells that had been 
successfully transfected (Figures 3.2.3 and 3.2.4). The protocol was first tested in HeLa cells 
due to their known ease to transfect. 
Untransfected cells were used as a control from which to determine what effect Lipofectamine 
and plasmid DNA had on cells (Figure 3.2.3 A-C). Lipofectamine only controls showed lower 
numbers of cells than the untransfected cells but did not look visibly different in any way 
(Figure 3.2.3 D-F). When cells were transfected using an empty vector they were visually 
identical to the untransfected cells also (Figure 3.2.3 G-I). In all controls no fluorescence was 
seen unlike in the cells transfected with pEGFP-C1 which were mostly positive for GFP (Figure 
3.2.3 J-L).   
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Following successful transfection in HeLa cells the same protocol was carried out in the 
1321N1 cell line (Figure 3.2.4). Untransfected cells showed no fluorescence in the GFP channel 
and were again used as a control from which to compare all other slides to (Figure 3.2.4 A-C). 
Lipofectamine only slides also showed a lower number of cells which was also seen with HeLa 
cells but were otherwise identical to untransfected cells (Figure 3.2.4 D-F). Lipofectamine plus 
empty vector also showed no difference to untransfected cells (Figure 3.2.2 G-I). Finally for the 
Lipofectamine and GFP condition, a small proportion of cells were positive for GFP, but this 
was in fewer cells when compared with the HeLa cells (Figure 3.2.4 J-L). 
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In order to determine which cells had been transfected with the CHMP2B plasmid (which had 
no tag), it would later be necessary for co-transfections with pEGFP-C1 to be carried out. All 
lipid-based transfection reagents (including Lipofectamine) work by creating small liposomes in 
an aqueous solution containing plasmid DNA. Hence, the liposomes sequester the DNA from 
the solution within the resultant lipid-DNA complexes; thus, liposomes created in a mixed 
solution of different DNAs should, in theory, contain a mix of the available DNAs. This property 
was utilised within this project to mediate delivery of CHMP2B together with pEGFP-C1 to 
cells. It was necessary to optimise the co-transfections protocol; initially using pBI empty 
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alongside pEGFP-C1. A constant level of 2µg of DNA was utilised, either as 2µg of pEGFP-C1 
alone or 1µg of pEGFP-C1 alongside 1µg pBI-empty. The same three volumes of Lipofectamine 
were tested as for the single transfections. 
Co-transfection efficiencies were significantly lower in HeLa cells when compared to pEGFP-C1 
only transfections for all volumes of Lipofectamine tested (ANOVA F(5,12)=15.734, p<0.001; 
Figure 3.2.5A). Although a trend towards higher volumes of lipofectamine yielding higher 
transfection efficiencies with 1.5μl lipofectamine having an average efficiency of 27.33±2.52% 
of GFP positive cells while 3μl of lipofectamine produced an average of 40±3.0% of GFP 
positive cells, there was no significant difference between the volumes. For 1321N1 cells, co-
transfection significantly reduced transfection efficiencies when performed with both 2µl and 
3µl Lipofectamine (ANOVA F(5,12)=21.157, p<0.001; Figure 3.2.5B). Again, a trend towards 
higher Lipofectamine volumes producing higher numbers of GFP positive cells was seen with 
1.5μl of lipofectamine only achieving an average of 6.67±1.53% of cells GFP positive while 3μl 
of lipofectamine producing on average 12.33±2.52% of cells, but this was not significant at any 
level. 
 
25 
 
 
3.3 Expression of CHMP2B 
Once the co-transfection protocol was optimised using pEGFP-C1 and pBI Empty, the 
expression model was created using the CHMP2B plasmids and pEGFP-C1 co-transfection in 
cell lines to investigate the effects that the mutant variant, CHMP2BI5, has on cellular 
morphology and localisation of CHMP2B.  
26 
 
HeLa cells were transfected first due to being easier to transfect than 1321N1 cells. 
Untransfected cells were used as a baseline from which to compare all other conditions to 
which were stained with anti-CHMP2B antibody and as expected showed no fluorescence in 
the GFP channel (Figure 3.3.1 A-D). Controls were set up to ensure any changes observed in 
the cells were due to the change in CHMP2B DNA and not any other factor.  Lipofectamine 
only controls contained fewer cells than other conditions but showed no visible differences in 
terms of cellular morphology or CHMP2B staining intensity when compared to the 
untransfected cells otherwise (Figure 3.3.1 E-H). Lipofectamine plus pBI empty controls also 
showed no visible differences to the untransfected cells (Figure 3.3.1 I-L). Lipofectamine plus 
pEGFP-C1 showed approximately 70% of cells positive for GFP in HeLa cells (Figure 3.3.1 M-P). 
The Lipofectamine plus CHMP2BWT condition also showed no visible difference when 
compared to the untransfected control. As the cells already expressed a high basal level of 
CHMP2B, no visual differences were seen and thus it was impossible to tell if the CHMP2B had 
been successfully transfected (Figure 3.3.1 Q-T). The final condition was Lipofectamine plus 
both pEGFP-C1 and CHMP2BWT and approximately 40% of cells were positive for GFP (Figure 
3.3.1 U-X).  
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Following transfections in HeLa cells, the same transfections were carried out in 1321N1 cell 
lines. Untransfected cells were used again as a baseline to compare all other conditions to 
(Figure 3.3.2 A-D). In the 1321N1 cells the Lipofectamine only control also showed fewer cells 
than other conditions as was also seen in HeLa cells but were visually the same as the 
untransfected cells (Figure 3.3.2 E-H). The Lipofectamine plus pBI Empty condition also showed 
difference to the untransfected cells (Figure 3.3.2 I-L). The Lipofectamine plus pEGFP-C1 
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condition showed approximately 20% of 1321N1 cells being positive for GFP expression (Figure 
3.3.2 M-P). This was much lower than in the HeLa cells. The Lipofectamine plus CHMP2B 
condition in 1321N1 cells was the same as with the HeLa cells and upon visual inspection 
looked the same as the untransfected cells (Figure 3.3.2 Q-T). The final condition of 
Lipofectamine plus pEGFP-C1 and CHMP2BWT showed only approximately 10% of cells being 
GFP positive in the 1321N1 cell line (Figure 3.3.2 U-X). As staining intensity changes for 
CHMP2B in either cell line were not readily apparent, quantification of mean pixel density was 
analysed to test for any differences. 
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The fluorescence intensity of CHMP2B staining in untransfected cells, cells transfected with 
CHMP2B and cells co-transfected with pEGFP-C1 and CHMP2B were analysed using ImageJ to 
determine if any increase in CHMP2B could be observed upon transfection. A baseline 
expression level of CHMP2B fluorescence was determined as the mean intensity of cells in the 
untransfected controls. All other cell staining intensities were compared to this baseline and 
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those which varied by more than two standard deviations from this baseline level would be 
determined to be clearly over-expressing and would be considered successful 
transfections(Figure 3.3.3). Neither the CHMP2B only transfections, nor CHMP2B and pEGFP-
C1 co-transfection produced values above this level.  Whether this reflected a high basal 
expression level of CHMP2B masking the expression of the transfected CHMP2B, whether it 
suggested a low level of transfection-induced expression or whether the transfection itself 
failed entirely could not be determined. Given the success of the pEGFP-C1 expression (which 
is a similarly sized plasmid and uses the same CMV promoter as the CHMP2B expression vector 
used here), the successful use of this CHMP2B plasmid in the Goldberg lab, the verification of 
DNA quality by spectrophotometry and agarose gel electrophoresis by other lab members 
(data not shown) and the well-established use of co-transfection of fluorescent reporters as a 
means to confirm expression of a gene of interest; the project proceeded on the assumption 
that GFP+ cells were also expressing CHMP2B WT or mutant, as appropriate. 
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3.4 Analysis of effects of CHMP2B mutants 
Cells were transfected using CHMP2BWT and CHMP2BI5 to determine if the expression of the 
mutant form caused any changes to localisation of CHMP2B and morphology of the cells. 
When comparing the CHMP2BWT and CHMP2BI5 transfected cells no differences could be 
observed in cellular morphology in either HeLa cells or 1321N1 cells (Figures 3.4.1 and 3.4.2). 
No difference was seen when comparing to untransfected cells around them either. Difficulty 
arose in trying to determine any changes to localisation of CHMP2B due to the high levels of 
basal expression already seen. No visible differences could be seen in each cell type (Figures 
3.4.1 and 3.4.2). 
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3.5 Semi-functional analysis 
3.5.1 Antibody Controls 
In order to determine if CHMP2B mutants played a role in altered cellular function the 
localisation of the glutamate transporters EAAT1 and EAAT2 were investigated. Initially 
staining controls were conducted to test the validity of the antibody and also allow for 
visualisation of basal glutamate transporter localisation. EAAT1 was tested first using HeLa 
cells. Unstained cells were used to compare to which showed no signal in the dsRED channel 
(Figure 3.5.1.1 A-C). The primary only stain showed no signal in the dsRed channel (Figure 
3.5.1.1 D-F), nor did the secondary only (Figure 3.5.1.1. G-I). In the HeLa cells when both 
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antibodies were applied sequentially there was still no signal in the dsRed  channel (Figure 
3.5.1.1. J-L). This shows there is no EAAT1 present within HeLa cells. 
 
The same antibody controls were then conducted for EAAT1 in the astrocytoma cell line 
1321N1. Untransfected cells were again used as a control from which to compare other 
conditions to (Figure 3.5.1.2 A-C). Neither the primary or secondary only stains showed any 
signal in the dsRed channel (Figure 3.5.1.2 D-F and G-I). In the full stain using both primary and 
secondary antibody showed positive staining for EAAT1 in all cells (Figure 3.5.1.2 J-L). 
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Staining controls were the conducted for EAAT2 in HeLa cells. Unstained cells showed no signal 
in the dsRED channel and were used to compare to (Figure 3.5.1.3 A-C). No staining was seen 
when either primary alone or secondary antibody alone were used (Figure 3.5.1.2 D-F and G-I). 
There was also no staining observed in HeLa cells when application of both antibodies also 
showing EAAT2 is not expressed in HeLa cells (Figure 3.5.1.3 J-L).  
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Finally the EAAT2 antibody was also tested in 1321N1 cell lines. Untransfected cells showed no 
signal in the dsRED channel (Figure 3.5.1.4 A-C). Both primary only and secondary only also 
showed no signal in the dsRED channel and were visually identical to the untransfected cells 
(Figure 3.5.1.3 D-F and G-I). Finally sequential used of the primary followed by the secondary 
antibody showed all cells stained positive for EAAT2 in 1321N1 cell lines (Figure 3.5.1.4 J-L). 
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High magnification images were taken of EAAT1 and EAAT2 staining in 1321N1 cell lines to 
determine normal localisation patterns within the cells (Figure 3.5.1.5). EAAT1 appeared to be 
present throughout the cell (Figure 3.5.1.5 A-C). EAAT2 also appeared to be expressed 
throughout the cells but there appeared to be a slightly higher density surrounding the 
nucleus. (Figure 3.5.1.5 D-F). Since HeLa cells did not contain any EAAT1 or EAAT2 only 1321N1 
cells were used for subsequent experiments. 
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3.5.2 Analysis of Localisation 
1321N1 cells were transfected with CHMP2BWT and CHMP2BI5 to determine if CHMP2B 
mutants had any effects on the localisation of EAATs within the cells. Firstly comparisons were 
made between with type and mutant transfected cells stained for EAAT1 (Figure 3.5.2.1). No 
differences were observed between the wild type (Figure 3.5.2.1 A-C) and the mutant 
transfected cells (Figure 3.5.2.1 D-F).  
 
The same was then repeated for EAAT2 (Figure 3.5.2.2). There was also no visible difference 
between the wild type (Figure 3.5.2.2 A-C) and mutant transfected cells (Figure 3.5.2.2 D-F).   
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4. Discussion 
Mutations in the ESCRT-III complex protein CHMP2B have been implicated in a variety of 
neurodegenerative diseases and are known to produce a rare familial form of frontotemporal 
dementia (Yamazaki et al., 2010; Isaacs et al., 2011). All other previous research has 
investigated either how these disease causing mutations in CHMP2B affect either neurons or 
the brain as a whole, but none have looked at CHMP2B in astrocytes despite astrocytes being 
implicated in virtually every neuropathology including frontotemporal dementia (Hallmann et 
al., 2017). Accordingly, this project aimed to carry out some initial investigations of CHMP2B in 
astrocytes; namely to confirm basal expression of the protein CHMP2B in astrocytes and 
determine what affect the FTD-associated mutation CHMP2B Intron 5 has on basic astrocyte 
biology, as indicated by cellular morphology and glutamate transporter localisation. 
4.1 Confirmation of CHMP2B expression in astrocytes 
While it has been previously suggested that CHMP2B is ubiquitously expressed throughout the 
body (Chassefeyre et al., 2015), no published research has ever explicitly investigated its 
expression in astrocytes. In order to confirm basal expression this project began by western 
blotting and immunofluorescence staining to elucidate basal expression and staining patterns 
in astrocytes. 
Confirmation of CHMP2B in astrocytes was achieved by western blotting using cell lysates. The 
western blot produced bands of approximately 25kDa which corresponds with the predicted 
molecular weight of CHMP2B in all cell types tested, including the astrocyte cell line 1321N1 
and normal human astrocytes (NHA). The protein band size observed in this project is 
consistent with other research using the same anti-CHMP2B antibody hence this is likely to be 
accurate (Belly et al., 2010; Ghazi-Noori et al., 2012). As previously stated, CHMP2B is already 
known to be expressed in HeLa cells (Atilla-Gokcumen et al., 2014) so they were used in this 
project as a positive control and yielded a band of identical weight to that seen in the 1321N1 
or NHA cells. Taken together, these data confirm that CHMP2B is indeed expressed in human 
astrocytes. 
A BCA assay was conducted prior to western blotting to determine protein concentration in 
cell lysates and to ensure equal protein loading in each lane. However, the intensity of the 
loading control band (beta actin) was seen to be much lower in the HeLa cells than in the 
1321N1 cells and NHAs. This indicates that the lanes were unequally loaded as beta actin is a 
constitutively expressed protein so all bands should have been equal (Taylor et al., 2013). One 
possible cause for this loading inconsistency could be due to the choice of protein assay. It has 
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been reported that certain factors can alter the accuracy of the BCA assay, including protein 
composition, post-translational modifications and interfering substances which may be 
present (Brady and Macnaughtan, 2015). The BCA assay was chosen due to its compatibility 
with the detergent-containing RIPA lysis buffer, however for future work an alternative assay, 
such as the Bradford assay, in combination with a compatible lysis buffer.  
Another potential explanation for the loading inconsistencies may have been degradation of 
the lysates following BCA assay due to freeze-thaw effects, as the BCA was conducted prior to 
initial freezing of the lysates. For any future work it would be better to conduct a BCA assay on 
the defrosted lysates immediately prior to running the blot to ensure protein concentrations at 
the time are being measured. 
Densitometry was conducted on the bands in order to normalise the CHMP2B concentration in 
each lane relative to beta actin in a semi-quantitative manner and permit the estimation of 
relative CHMP2B expression in each cell type, taking into account the inconsistent protein 
loading. Densitometry has been reported to be a reliable method for quantification of western 
blot data as opposed to visual inspection the blot (Taylor et al., 2013). Densitometry suggested 
that the HeLa had the highest relative CHMP2B expression whilst the normal human astrocytes 
had the lowest. Unfortunately, due to inconsistent blot quality densitometry could only be 
carried out on one single blot, so full conclusions regarding relative expression levels were not 
possible. If these results are validated then it could imply that astrocytes express a higher level 
of CHMP2B than non-glial cells. It has been reported that ESCRTs are required for the 
formation of exosomes via MVB formation (Verkhratsky et al., 2016). Since astrocytes are vital 
for release and uptake of glutamate at synapses, this could imply a greater need for CHMP2B 
and ESCRTs in astrocytes. 
Immunofluorescence staining of cell lines with an anti-CHMP2B antibody was conducted to 
visually confirm basal expression of CHMP2B in astrocytes and identify any specific localisation 
patterns within cells. High levels of staining were present in both 1321N1 and HeLa cell types 
and was seen to extend throughout the cell in a punctate manner. The staining pattern 
observed was similar to that seen in another study which had utilised this antibody in neurons 
(Bodon et al., 2011). This result provides further confirmation that CHMP2B is expressed in 
astrocytes, as 1321N1 cells are derived from astrocytoma tissue. ImageJ was used to analyse 
the fluorescence intensities of the CHMP2B in the two cell lines which showed no significant 
difference. This result roughly corresponds with that observed with the densitometry, where 
1321N1 and HeLa cell lysate CHMP2B band densities were similar (although statistical analysis 
was not possible). Normal human astrocytes were unavailable for this and the subsequent 
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stages of this project due to a range of factors including inconsistent supply and manufacturer 
media shortages. This can be a common issue when using primary human cells, whose 
availability depends on human donation as a by-product of biopsies and which utilise 
extremely defined medium compositions. Based upon the densitometry data, it would not be 
unexpected that NHAs would have higher fluorescence levels than the cell lines, but this 
should form the basis of further studies. 
4.2. Creation of expression model 
In order to transiently express wild-type and mutant CHMP2B in cells to assess their relative 
effects on phenotype, an expression model was created using the transfection reagent 
Lipofectamine 3000. Lipofectamine reagents have become some of the most widely used 
transfection reagents and are considered the gold standard for transfection reagent (Cardarelli 
et al., 2016). Prior to the project different transfection methods had been tested in the lab and 
Lipofectamine 3000 was deemed to be the most effective method for astrocyte transfections 
(Dr Vicky Jones, personal communication). The “Lipofection” method works by DNA, which is 
negatively charged, being contained within cationic liposomes which are formed by the 
Lipofectamine reagent. These DNA-loaded liposomes then fuse with the cell membrane which 
allows for the release of the DNA into the cell (Balazs and Godbey, 2011; Sandbichler et al., 
2013). If DNA encoding different proteins are mixed, in this case pEGFP-C1 and CHMP2B, the 
liposomes should take up both DNAs and both would be released into the cell. This technique 
has been used widely as a means to co-express a gene of interest alongside a reporter gene, 
such as a fluorescent protein, in many cell types including astrocytes (Montana et al., 2004; Ni 
and Parpura, 2009; Malarkey and Parpura, 2011). Hence, it was reasonable to assume that 
cells which were positive for GFP in the co-transfected experiments would also be positive for 
CHMP2B. 
To first optimise the single transfection protocol, different ratios of plasmid DNA (pEGFP-C1) 
and lipofectamine reagent were compared to determine which provided the highest 
transfection efficiencies (as measured by the number of GFP+ cells). 
 For the HeLa cells a greater difference in transfection efficiency was seen when a higher 
amount of DNA was used but not when a higher volume of lipofectamine was used. In 1321N1 
cells a higher volume of lipofectamine increased the transfection efficiency but a higher DNA 
volume did not increase efficiency. Generally, 1321N1 cells produced much lower GFP positive 
cells compared to HeLa cells. This was also the case when co-transfecting which were lower for 
both cell types when compared to the single transfection.  
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Increasing of both DNA and Lipofectamine reagent increased the transfection efficiencies in 
both cell types. This is likely to be due to a higher number of liposome complexes containing 
more DNA being formed and therefore a greater chance of the DNA being internalised by the 
cells. While HeLa transfections reached a consistent level of around 70%, in 1321N1 cells 
transfection efficiencies remained low at around 20%. This would be expected as all brain cell 
types, astrocytes included, have been reported to be somewhat hard to transfect (Marucci et 
al., 2011).. The confluency of cells and overall cellular morphology following transfection was 
also investigated as a measure of cellular toxicity mediated by the transfection reagent. No 
significant difference was seen in either case upon any treatment, suggesting that the 
Lipofectamine had no toxic effect on the cells tested and was suitable for use in the planned 
experiments. 
4.3 Analysis of effects of CHMP2B mutants 
This project aimed to determine if a mutant form of CHMP2B affected the cellular morphology 
of astrocytes. When the transfection protocol had been optimised cells were either 
transfected with plasmids encoding wild-type CHMP2B (CHMP2BWT) or plasmids encoding the 
most common FTD causing mutant variant of CHMP2B, the truncated CHMP2B intron 5 variant 
(CHMP2BI5) (van der Zee et al., 2008; Belly et al., 2010). When comparing cells transfected 
with CHMP2BWT and those transfected with the mutant form CHMP2BI5, no differences were 
noted in astrocyte morphology – a phenomenon which is increasingly being linked with 
neurodegenerative disorders (Olabarria et al., 2010; Jones et al., 2017). Similarly, no obvious 
alteration in the localisation of CHMP2B as observed upon expression of the intron 5 variant; 
however it was difficult to visualise transiently expressed CHMP2B above basal expression. 
One paper which looked at the effects of CHMP2B mutations in neurons noted that the mutant 
CHMP2B which was stained using an anti-tag antibody formed clusters and aggregates unlike 
the WT form (Belly et al., 2010). It was impossible to differentiate between endogenously 
expressed and transiently expressed CHMP2B in this project as the CHMP2B plasmids available 
did not contain a specific tag which could have been used to detect the transfected CHMP2B 
only. Another plasmid containing CHMP2B with a FLAG tag was received from Y. Goldberg 
towards the end of the project which would be useful for any future research into CHMP2B, 
however it was too late to use during this project. Use of an anti-FLAG antibody would allow 
for differentiation between basal CHMP2B and transfected (FLAG-tagged) CHMP2B, as has 
been carried out elsewhere (Bodon et al., 2011; Cheruiyot et al., 2014). 
The morphology of astrocytes is vital to their functioning within the brain. Reactive gliosis is 
the process by which astrocytes change their shape and size in response to central nervous 
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system damage (Burda and Sofroniew, 2014). Reactive gliosis has been observed in 
neurodegenerative disorders previously and it was conceivable that introduction of the FTD-
causing CHMP2BIB mutant could cause a change in cell morphology (Verkhratsky et al., 2014; 
Pekny and Pekna, 2016). No changes to either astrocyte (1321N1) or HeLa morphology were 
observed in this research. This could either be due to the CHMP2B intron 5 mutant having no 
effect on astrocyte morphology or due to experimental limitations. For example, it was hard to 
differentiate between transfected and non-transfected cells using the anti-CHMP2B antibody 
alone. This could be explained by the relatively high basal expression levels masking additional 
transient expression, or may be due to relatively poor levels of overexpression in the 
transfected cells caused by, for example, not enough DNA being transfected into the cells, as it 
was known the transfection levels were extremely low within the 1321N1 cell lines. There may 
have been issues already within the cells which may have affected the CHMP2B plasmid 
expression (e.g. underlying infection) or that the cells may already exhibit a changed shape 
because they are derived from an astrocytoma, rather than normal cells.  
The glutamate transporters EAAT1 and EAAT2 are responsible for the uptake of over 95% of 
glutamate in the brain and their availability is vital for normal functioning of astrocytes. 
Staining for the glutamate transporters EAAT1 and EAAT2 were conducted in both HeLa cells 
and 1321N1 cells. As expected the results showed no staining for either transporter in HeLa 
cells, as these are brain specific transporters (Ugbode et al., 2017) . Comparisons showed no 
differences in EAAT1 or EAAT2 localisation in the 1321N1 cells when expressing CHMP2BI5 
compared to WT. This could imply that the CHMP2B Intron 5 mutation is not implicated in 
astrocyte glutamate handling and/or may not be linked to localisation of these transporters. 
Alternatively, as outlined above, it may be that the levels of expression were not sufficient to 
induce any changes.  
Project limitations 
During this project, frequent issues were experienced with transfecting the cell lines and it was 
only in the final few months of the project that the transfections began working. There were 
consistent issues regarding infection in the communal lab for the duration of the project and 
also there were problems with regards to DNA quality which set the project back. Freeze-
thawing of the plasmid DNA may have caused degradation and therefore it is possible that not 
enough intact plasmid DNA was being added to the transfection mix which could account for 
some of the transfection problems seen within this project. 
Transfections remained difficult with the 1321N1 cell line, which have been reported to be 
particularly difficult to transfect (Marucci et al., 2011).  The highest transfection efficiencies 
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achieved in this cell line was only 22% but this decreased to an average of 12% when 
attempting co-transfections using both CHMP2B and pEGFP-C1. HeLa cells were found to be 
much easier to transfect than 1321N1 cells and showed transfection efficiencies of over 70% 
when only transfecting pEGFP-C1 and this decreased to 40% when co-transfecting.   
Due to the length of the project, the low transfection levels were considered to be manageable 
as most of the project was immunofluorescence based and it was not essential that a large 
proportion of cells would need to be expressing the desired protein as would have been the 
case for functional analysis. It is a possibility that the lack of any differences observed in this 
project could be due to the amount of DNA being transfected not being enough to have a 
significant effect due to the high basal levels of CHMP2B. 
4.4 Future Works 
Whilst this research did not find any conclusive results in regards to how CHMP2B mutations 
may affect astrocyte morphology or glutamate transporter localisation it has identified that 
CHMP2B is expressed in astrocytes. No other research has shown this previously and this 
opens up a new area of research opportunity in regards to how CHMP2B may play a role in 
neurodegeneration via astrocyte pathology. 
Further research should aim to confirm robust expression of transfected CHMP2B using a 
plasmid containing a FLAG tag and anti-FLAG antibody to identify transfected CHMP2B as 
opposed to basal CHMP2B. This would allow for confirmation of transfection without the need 
for GFP, allow for localisation differences between WT and I5 to be assessed and permit clear 
conclusions to be drawn. 
Other future work should aim to begin investigating if CHMP2B mutants that have been seen 
to produce FTD also affect astrocytes in similar ways to neurons. Previous research has already 
elucidated some effects in neurons but moving forward the effects of mutant CHMP2B in 
astrocytes needs to be investigated. One potential route of investigation could be to compare 
levels of CHMP2B in neurons and astrocytes. It was seen in this project that astrocytes appear 
to express a high basal level of CHMP2B; it would be interesting to compare this to both 
neurons and other glial cells such as microglia which may also play a role in neurodegeneration 
during FTD as this could indicate astrocytes may play more of a role in disease progression 
than is currently thought.  
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